Kornimate/medical-research-clean huggingface dataset:
effect of jaeumgeonbi-tang on chronic subjective dizziness

Conditions: Chronic Subjective Dizziness

Summary: the goal of this study is to assess the safety and efficacy of jgt (jaeumgeonbi-tang). a randomized, double-blind, parallel-group, placebo-controlled clinical trial was conducted and changes in symptoms and quality of life of the patients were evaluated.

this study's protocol was designed to assess the efficacy of jgt (jaeumgeonbi-tang) for chronic subjective dizziness. * this design of the study is a randomized, double-blind, parallel-group, placebo-controlled design. * symptoms and quality of life of chronic subjective dizziness patients will be evaluated. * dizziness severity and quality of life of the patients will be evaluated using dhi (dizziness handicap inventory) (1) before treatment (baseline), (2) after 2 weeks, and (3) after 4 weeks of jgt treatment. * blood samples of the patients will be gathered before and after jgt treatment for pathophysiological analysis.

Eligibility criteria:
\[inclusion criteria\] * chronic subjective dizziness patients, aged from 20 to 65 * dhi (dizziness handicap inventory) score ≥ 24 * those who can fully comprehend the general protocol of this study and voluntarily agree to participate \[exclusion criteria\] * inner ear disease (benign paroxysmal positional vertigo, vestibular neuritis, meniere's disease, etc.) * dizziness secondary to specific diseases such as hypoglycemia, recent stroke (within the last 6 months), or heart disease. * use of medications that could influence the result of the study (anticonvulsants, sedatives, antidepressants, sleeping pills, prostate medicine, parkinson's drug, dementia drug, etc.) * pregnancy, breastfeeding, or plans of becoming pregnant * functional dyspepsia (persistent, recurring abdominal pain, or discomfort) * other allergic diseases * ineligibility for other reasons in the opinion of the research clinician (when the physician determines that there are significant physical or mental defects that the patient cannot understand and follow the protocol)

Keywords: chronic subjective dizziness oxidative stress
clotrimazole vaginal tablet vs fluconazole for severe vulvovaginal candidiasis

Conditions: Candidiasis, Vulvovaginal

Summary: the study is focused to prove that the efficacy and safety of clotrimazole vaginal tablet vs fluconazole for the treatment of severe vulvovaginal candidiasis

the current study is evaluating both the efficacy and safety of the 2 doses of 500 mg clotrimazole vaginal tablet administered intravaginally( at day 1 and day 4) v.s 2 doses of 150 mg fluconazole( at day 1 and day 4) for treatment of severe vulvovaginal candidiasis.the number of participants with adverse events as a measure of safety and tolerability.

Eligibility criteria:
inclusion criteria: 1. vulvovaginal candidiasis infection is diagnosed, the symptoms evaluated using a numerical rating system based on severity (absent=0; mild=1; moderate=2; severe=3) with a minimum vvc composite signs/symptoms score of 7 2. subject completes the informed consent process 3. subject agrees to take study medication when scheduled 4. subject complies with all clinical trial instructions. commits to all follow-up visits exclusion criteria: 1. had any other sexually transmitted disease or gynaecological abnormality requiring treatment 2. had a disease known to predispose to candidiasis such as diabetes mellitus, or were receiving antibiotics or corticosteriods 3. were pregnant 4. had used antifungal medication in the week before entry 5. were expected to menstruate within seven days of the start of treatment 6. infected more than one candida species
hybrid assistive limb effect on jump height: a clinical study

Conditions: Sport Injury

Summary: the aim of this study is to investigate the effect of exercises performed with the hybrid assistive limb device on the jump height of healthy non-athlete individuals.

cyberdyne waist type device will be worn by attaching 3 electrodes to the waist area and then attaching the device to the waist and legs with the help of belts. then, the appropriate modes will be selected for the participant with the adjustments made on the device. it has 3 modes; cvc, the mode that produces torque value, that is, movement, according to muscle activation with only the bioelectric signals received from the person's skin. cac, the mode that produces movement by presenting automatic values to the participant with data designed according to the specific software and algorithm of the device. cic, the mode that produces movement completely according to the participant's control. in our study, investigators will produce movement according to the muscle activation created by the participant using the cvc mode. in this way, investigators will provide the brain-muscle relationship and motor learning parameters. the exercises will be applied for 30 minutes, 5 days a week, for a total of 40 sessions.

Eligibility criteria:
inclusion criteria * being between 20 and 40 years old. * tall individuals over 120 cm (for accurate visual feedback in the assessment of jump height) * weighting less than 100 kg * people who can perceive and follow the given instructions without any problems * people who have not had any surgery in the last 6 months * people who are not allergic to electrodes * they should not have any skin tissue related disorders. * people who do not use pacemakers * people who do not have a history of seizures or a risk of seizures (epilepsy). * they should not have heart and respiratory problems. * people who have not experienced back pain in the last 3 months. * people whose waist circumference is not more than 120 cm and whose thigh circumference is not more than 80 cm. * no orthopedic or neurological problems that will affect the balance mechanism (e.g. vertigo, cerebellum damage, ataxia). * not having used a waist type hybrid assistive limb device before * not having worked with visual feedback devices such as tecnobody d-wall before * not having worked with any of the cyberdyne hybrid assistive limb devices before exclusion criteria * people with back pain or who have had surgery on their back * having had surgery within the last 6 months.
effects of walking apnea at high lung volume on hypoalgesia

Conditions: Pain; Hypoxemia; Hypercapnia; Apnea

Summary: the aim of this randomized controlled study is to explore the hypoalgesic response of a 6 minutes of intermittent walking apneas training session at high lung volume in healthy subjects; also, as secondary objectives, to analyze the cardiovascular and respiratory response produced during the intervention.


Eligibility criteria:
inclusion criteria: * asymptomatic subjects aged between 18 and 64 years. exclusion criteria: * cardiovascular, respiratory, metabolic, neurological or osteomuscular signs or pathologies. * history of epilepsy. * pregnant * pharmacological treatment. * participants who present any type of pain on the day of the measurements or who have frequently suffered pain during the previous 4 weeks.
the effect of computerized cognitive training on mood and thinking style amongst patients in inpatient settings

Conditions: Depression; Anxiety; Anhedonia

Summary: the purpose of this randomized controlled trial is to establish feasibility and provide initial estimates of efficacy of two computerized cognitive training procedures (a form of positive mental imagery training, pmit, and a form of cognitive control training, cct) delivered as adjuncts to treatment as usual (tau) in inpatient mental health treatment settings.


Eligibility criteria:
inclusion criteria: * aged 18 years or above * sufficient german language skills * receiving treatment in a participating inpatient clinic during the timeframe of the study (i.e. they must be able to complete the training entirely within their admission). exclusion criteria: * existence of a condition or circumstances that would interfere with completion of the study procedures (e.g. severe visual impairment, neurological problem, acute psychosis or substance withdrawal symptoms)

Keywords: positive affect mental imagery cognitive bias modification cognitive control training
auditory stimulation effects on sleep and memory in patients with epilepsy

Conditions: Epilepsy

Summary: this study will investigate the role of coordinated brain rhythms during sleep in memory consolidation and determine whether playing precisely timed brief bursts of noise can enhance these rhythms and improve memory in epilepsy inpatients with implanted hippocampal electrodes.

the investigators will test the hypotheses that coordinated brain rhythms during nonrapid eye movement sleep are associated with memory consolidation and can be enhanced with auditory stimulation (playing precisely timed brief bursts of quiet noise) to improve memory. the investigators will measure differences in sleep and memory performance in epilepsy inpatients with implanted hippocampal electrodes and continuous full scalp eeg monitoring under three overnight sleep conditions: a baseline night; a memory night during which sleep-dependent memory consolidation is assessed with the finger tapping motor sequence task (mst) with training prior to sleep and testing the next morning; and a stimulation night during which participants train on the mst, have precisely timed auditory stimulation during the sleep that follows, and are tested on the mst in the morning.

Eligibility criteria:
inclusion criteria: * inpatients with epilepsy * aged 12-65 * undergoing clinically indicated continuous scalp and intracranial eeg monitoring with implanted hippocampal electrodes * fluent in english * able to give informed consent/assent (for minors aged 12-17 or adults with an appointed guardian) exclusion criteria: * intellectual disability impairing ability to perform task * motor problems that preclude finger tapping task * previous surgery anticipated to disrupt coordination of sleep oscillations in the circuitry of interest

Keywords: sleep memory auditory stimulation spindles intracranial monitoring hippocampal ripples slow oscillations
effect of oral health educational program on oral health quality of life of group of type1 diabetes children

Conditions: Oral Health Related Quality of Life

Summary: the study is a before and after study made to assess the oral health related quality of life after oral health educational program on children with type1 diabetes mellitus. the main questions it aims to answer are: * oral health related quality of life * caries experience participants will answer oral health quality of life questionnaire and will be checked for dmf and def indices and then given an oral health education program and followed up after 3 months.

the oral health educational program will be conducted in arabic in the form of flyers given to the children and their parents plus modeling on brushing habits on a cast and tooth brush.the educational program will emphasize on three main messages (brushing twice daily, healthy diet compatible with their disease and regular dentist visits). data in the flyer contained dietary tips as well as oral hygiene habits, design was made by the primary investigator. the child oral health related quality of life will be measured by the validated arabic child perception questionnaire (cpq8-10) dental history, def and dmf indices will be measured by dental chart that will be modified to include a section for current medications. to avoid selection bias all participants matching inclusion criteria in examination day will be included and all outcomes will be reported to avoid reporting and detection bias. study size: to the best of our knowledge there are no other studies found in literature to estimate a sample size so this study is going to be a pilot study with sample size of 50 child. statistical method: categorical data will be represented as frequency (n) and percentage (%) and will be analyzed using chi square test. numerical data will be investigated for normality by checking the data distribution, calculating the mean and median values and using kolmogorov-smirnov and shapiro-wilk tests. if the data was normally distributed, it will be shown as mean and standard deviation values and an independent t-test will be used for analysis. if the assumption of normality was violated; the data will be presented as median and range values and will be analyzed using mann-whitney u test. the significance level will be set at p ≤0.05 for all tests. statistical analysis will be performed with ibm® spss® statistics version 26 for windows.

Eligibility criteria:
inclusion criteria: * children of both sexes * age from 8 to 10 years old * diagnosed with type 1 diabetes mellitus exclusion criteria: * children with other systemic diseases * parents who refuse participation
methimazole in graves' disease - comparing the computer-aided treatment digithy versus usual care

Conditions: Graves Disease

Summary: the goal of this clinical trial is to compare two methods of guiding methimazole therapy in patients with graves' disease: methimazole dose adjustments based on a new semi-automated computer-guided treatment (based on a mathematical model) or based on the treating physician's decision (i.e. usual care). the main question it aims to answer is whether semi-automated computer-guided treatment is not inferior to usual care in terms of safety, the time it takes to achieve euthyroidism and the methimazole dose required.


Eligibility criteria:
inclusion criteria: * active graves' hyperthyroidism \[thyroid-stimulating hormone \<0.1 mu/l, elevated free thyroxine levels (ft4) above the upper limit of normal and positive thyrotropin receptor antibody (trab) according to local laboratory results\], measured within the last month prior to the inclusion date * patients not yet receiving antithyroid treatment, or having received antithyroid treatment continuously for less than 4 weeks, or relapse or recurrence of graves' hyperthyroidism defined as patients previously having received and discontinued treatment with antithyroid drugs for at least 4 weeks) * age 18 years or older * provision of written informed consent exclusion criteria: * previous treatment with radioactive iodine * ongoing antithyroid treatment for more than one month * pregnancy * treatment with propylthiouracil
a prospective, randomized controlled study of the probiotics as adjuvant treatment for bacterial vaginosis

Conditions: Bacterial Vaginosis

Summary: the investigators are trying to determine if oral probiotics(umeta-mimi,30 days) with metronidazole vaginal suppositories (7 days) is better than using metronidazole vaginal suppositories(7 days) only in preventing the recurrence of bacterial vaginosis

studies have shown that oral probiotics(umeta-mimi) can significantly promote the recovery of vaginal flora mainly because intestinal microbiota can migrate and affect vaginal microecology. this project aims to evaluate the efficacy of oral probiotics(umeta-mimi,30 days) with metronidazole vaginal suppositories(7 days) in the treatment of bacterial vaginosis (bv) and to explore the correlation between vaginal flora and fecal flora by detecting the metagenomics of vaginal secretions and intestinal feces at the time of baseline phase,14 days after treatment， the first month after treatment, 5-7 days after third menstruation after treatment and 5-7 days after sixth menstruation after treatment

Eligibility criteria:
inclusion criteria: 1. aged 18 to 55 years old, with history of sexual activity, 2. amsel criterion for diagnosing bv 3. sign informed consent exclusion criteria: 1. history of systemic organic diseases or psychiatric diseases 2. planning for or during pregnancy, lactation, menstruation 3. within 5 days of onset of the disease, any antibiotics has been used 4. long-term use of contraceptives or immunosuppressant 5. anaphylactic constitution or allergic to known ingredients of research drugs 6. no same fixed partner (rsp) before and after treatment
the doctors for coronavirus prevention project thanksgiving / christmas messaging campaign

Conditions: Covid19

Summary: facebook ads with physician-delivered videos were shown before the thanksgiving and christmas holidays and focused on staying safe during the covid pandemic by limiting travel and mask-wearing.

the investigators used facebook ads to show a 20 second video clip recorded by massachusetts general hospital, harvard and lynn community health center doctors (6 people in all) to approximately 20,000,000 facebook users. the ads will be shown before the thanksgiving and christmas holiday and will focus on staying safe - limiting travel and mask-wearing. the investigators will randomize exposure to the ad campaign at the zip code or county level to ask: do the videos change mobility and thanksgiving and christmas holiday travel? do they reduce the spread of covid-19? are there spillover impacts from the video messages? for example, if individuals decide to stay home, then do the geographical regions that tend to be visited by people from treated areas experience any effects, either through information spillovers or through a reduction in travel?

Eligibility criteria:
inclusion criteria: - individuals viewing the ads must be facebook users, 18 years and older. facebook will decide specifically which users receive the messages within a target geographical area (zip or county). exclusion criteria: -
early endoscopic ultrasound - based sphincterotomy or conservative treatment in severe biliary pancreatitis

Conditions: Pancreatitis Acute Biliary

Summary: the primary purpose of this trial is to determine whether an early early endoscopic ultrasound (eus) immediately followed by an endoscopic sphincterotomy (es) in case of bile duct stones may improve outcomes in patients with predicted severe acute biliary pancreatitis (abp).

the management of acute biliary pancreatitis (abp) remains controversial. although early decompression of the bile duct is deemed potentially beneficial, previous randomised studies failed to show the benefit of early endoscopic sphincterotomy (es) except in selected cases. however, those studies did not use recent non invasive diagnostic methods such as eus. methodology: patients in the study group undergo eus followed by es in case of common bile duct stones within 48 hours of the onset pf symptoms; the control group includes patients with predicted severe abp undergoing conservative treatment or endoscopic sphincterotomy (without eus) within 72 hours of the onset of symptoms in case of cholangitis or biliary obstruction.

Eligibility criteria:
inclusion criteria : * age \> 18 * predicted severe acute biliary pancreatitis (including age \> 80, bmi \>30, pre-existing organ failure, modified glasgow score \> 3) * timespan between onset and randomization \< 48 hrs * informed consent signed by patient or liable person in case of emergency exclusion criteria : * non biliary pancreatitis * non severe pancreatitis * age \< 18 * timespan between onset and randomization \> 48 hrs * absence of consent * ongoing pregnancy * no social security insurance

Keywords: ercp eus pancreatitis biliary severe interventional endoscopy choledocolithiasis
renal impairment study with asp1941

Conditions: Type 2 Diabetes Mellitus

Summary: a study to investigate if the pharmacokinetics of asp1941 is different in type 2 diabetes mellitus (t2dm) patients with different grades of renal failure compared with t2dm patients with normal renal function and healthy volunteers.


Eligibility criteria:
inclusion criteria: * patient with stable type 2 diabetes mellitus or healthy subject * subject must have pre-dose estimated glomerular filtration rate (gfr) values (modification of diet in renal disease (mdrd) method) at screening of: * \>90 (normal renal function) * 60-90 (mild renal impairment) * 30-60 (moderate renal impairment) * 15-30 (severe renal impairment) * bmi between 25.0-40.0 kg/m2, inclusive * fasted plasma glucose (fpg) \ 5.6 mmol/l (healthy volunteers) exclusion criteria: * patients with type 1 diabetes * pulse \ 90; sbp \>160 mmhg; dbp \> 100 mmhg * t2dm patients who are not on a stable regimen for their current medication (1 month or 5 half lives, whichever is longer) to control their disease * healthy volunteers: any of the liver function tests above the upper limit of normal * t2dm: the liver function tests should be within the following ranges: * ast/alt: \<2 x uln * bilirubin: \<1.5 x uln * alk phos: \< 1.5 x uln * patients with renal impairment who have a history of a clinically significant illness (other than renal diseases and t2dm and associated clinical symptoms), medical condition, or laboratory abnormality within 3 months prior to screening * patients with renal impairment who have not been on a stable dose of concomitant medications for at least 2 weeks for at least 2 weeks (or 5 halflives, whichever is longer) and/or for whom dose changes are likely to occur during the study * patients with t2dm treated with a diet only * t2dm patients with recent evidence (e.g within the last 6 months) of severe hypoglycemia, for example plasma glucose \< 3mmol/l (\<55 mg/dl), help from others to resolve the hypo or requiring hospitalization * t2dm patients with a hemoglobin value \< 9 g/dl (5.6 mmol/l)

Keywords: renal impairment asp1941 pharmacokinetics
statin therapy in patients with vasospastic angina

Conditions: Angina Pectoris, Variant; Statins, HMG-CoA

Summary: the purpose of this study is to evaluate whether statin is effective in the treatment of vasospastic angina.


Eligibility criteria:
inclusion criteria: * age 19 and more * vasospastic angina * ldl less than 160mg/dl * written consent exclusion criteria: * coronary artery stenosis more than 50% or ischemic coronary disease * history of percutaneous coronary intervention * cerebrovascular diseases or peripheral * dyslipidemia required statin therapy * heart failure, arrhythmogenic right ventricular dysplasia, hypertrophic cardiomyopathy, akinesia or aneurysm on left ventricular wall, anomaly of coronary artery * nyha iii and iv * arrhythmia * primary cardiac electrical diseases * cardiac pacemaker or implantable defibrillator * pregnancy or breast feeding * life expectancy less than 2 years

Keywords: statin vasospastic angina
hemodialysis-induced renal perfusion decline: unraveling the pathophysiological mechanisms linking intradialytic circulatory stress to residual renal function loss

Conditions: End-Stage Renal Disease Requiring Haemodialysis

Summary: residual renal function (rrf) plays a critical role in quality of life and survival in hemodialysis (hd) patients but characteristically declines after the initiation of hd. owing to incomplete understanding of the pathophysiology underlying rrf decline, protective strategies remain limited. the aim of this study was to characterize the changes in renal perfusion in incident hd patients with preserved rrf during dialysis sessions and to provide new strategies for rrf preservation.


Eligibility criteria:
inclusion criteria: * (1) adult patients with end-stage renal disease (esrd) within 3 months of commencing hd; (2) preserved rrf defined as urinary output \>500 ml/24 h or egfr ≥3 ml/min/1.73 m² exclusion criteria: * (1) known allergy to sulfur hexafluoride microbubbles (sonovue®) microbubbles; (2) vascular access dysfunction; (3) combined peritoneal dialysis; (4)severe cardiopulmonary disease; (5) active infection or malignancy; (6) communicable diseases; (7) pregnancy or breastfeeding; (8) participation in other clinical trials.

Keywords: hemodialysis